Payment overview · 2025
General Payments
$7,249.50
106 reported records · 24 companies
Healthcare provider profile · identity verified
Arthur M Kozin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · WEST NYACK, NY · NPI 1659339513
Verified facts
What the public records show
CMS Open Payments records show Arthur M Kozin, M.D. received $7,249.50 in general payments during 2025 across 106 reported records.
Vifor Pharma, Inc. accounted for 72.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Veltassa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xeljanz by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $5,243.99 | 72.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.84 | 3.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.81 | 2.2% | 8 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $158.25 | 2.2% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $143.19 | 2.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $139.71 | 1.9% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $135.05 | 1.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $108.83 | 1.5% | 4 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $94.24 | 1.3% | 4 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $94.06 | 1.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.71 | 1.2% | 4 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $83.46 | 1.1% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $79.98 | 1.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $75.59 | 1.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.98 | 1.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.49 | 0.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $49.91 | 0.7% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.98 | 0.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.81 | 0.6% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $35.96 | 0.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.46 | 0.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.34 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.99 | 0.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.87 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,695.00 | 3 |
| Food and Beverage | $2,240.05 | 86 |
| Education | $158.25 | 15 |
| Travel and Lodging | $156.20 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $5,243.99 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $252.84 | 12 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $158.25 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $139.71 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $135.05 | 4 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $94.24 | 4 | 2025 |
Source payment records
|
|||||
| Venxxiva Normalized: venxxiva |
Drug | Cycle Pharmaceuticals Inc | $94.06 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $83.46 | 3 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $81.91 | 3 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $79.98 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $75.59 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.98 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.38 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $61.37 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $58.14 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.49 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.49 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $47.35 | 2 | 2025 |
Source payment records
|
|||||
| TRYVIO Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $35.96 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $31.46 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 230 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
230 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 460 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 103 |
| Farxiga | Dapagliflozin Propanediol | 230 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 59 |
| Telmisartan | Telmisartan | 198 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 51 |
| Eplerenone | Eplerenone | 187 | 54 |
| Allopurinol | Allopurinol | 182 | 53 |
| Furosemide | Furosemide | 162 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 40 |
| Potassium Citrate Er | Potassium Citrate | 135 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 123 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 40 |
| Metformin Hcl | Metformin Hcl | 114 | 30 |
| Omeprazole | Omeprazole | 114 | 35 |
| Lisinopril | Lisinopril | 113 | 33 |
| Famotidine | Famotidine | 112 | 34 |
| Valsartan | Valsartan | 111 | 29 |
| Spironolactone | Spironolactone | 107 | 34 |
| Alprazolam | Alprazolam | 105 | 25 |
| Prosol | Parenteral Amino Acid 20% No.1 | 105 | suppressed |
| Irbesartan | Irbesartan | 96 | 28 |
| Labetalol Hcl | Labetalol Hcl | 96 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 34 |
| Jardiance | Empagliflozin | 84 | 21 |
| Losartan Potassium | Losartan Potassium | 75 | 25 |
| Calcitriol | Calcitriol | 69 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 22 |
| Carvedilol | Carvedilol | 68 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 23 |
| Kerendia | Finerenone | 62 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 62 | 21 |
| Simvastatin | Simvastatin | 62 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Eliquis | Apixaban | 57 | 13 |
| Prednisone | Prednisone | 56 | 17 |
| Potassium Chloride | Potassium Chloride | 54 | 20 |
| Atenolol | Atenolol | 53 | 14 |
| Ozempic | Semaglutide | 53 | 12 |
| Chlorthalidone | Chlorthalidone | 52 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Gabapentin | Gabapentin | 46 | 14 |
| Vascepa | Icosapent Ethyl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 14 |
| Torsemide | Torsemide | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Colchicine | Colchicine | 42 | 16 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | 17 |
| Ramipril | Ramipril | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 12 |
| Veltassa | Patiromer Calcium Sorbitex | 37 | 11 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Indapamide | Indapamide | 29 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 25 |
| Methylprednisolone | Methylprednisolone | 28 | 23 |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | 11 |
| Doxepin Hcl | Doxepin Hcl | 26 | 13 |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Tacrolimus | Tacrolimus | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Finasteride | Finasteride | 23 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Penicillamine | Penicillamine | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Xphozah | Tenapanor Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Yuvafem | Estradiol | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xeljanz | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,249.50 · 106 records | Vifor Pharma, Inc. | ABRYSVO, ACTHAR, AREXVY, CAPVAXIVE, COMIRNATY, CRYSVITA, FARXIGA, FUROSCIX, Fabhalta, GARDASIL 9, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LEQVIO, LUPKYNIS, MOUNJARO, PREVNAR 20, RAYALDEE, SHINGRIX, SYMPLICITY G3, TARPEYO, TAVNEOS, TRYVIO, UPLIZNA, VELPHORO, VOYXACT, Vanrafia, Veltassa, Venxxiva, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error